Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Aliment Pharmacol Ther ; 14(6): 737-44, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10848657

ABSTRACT

BACKGROUND: Few data are available on the efficacy of second-line H. pylori eradication regimens. AIM: To compare the efficacy of either omeprazole or ranitidine in a second-line quadruple regimen in patients with duodenal ulcer or erosive duodenitis. PATIENTS AND METHODS: A total of 37 patients with erosive duodenitis and 119 with duodenal ulcer who have failed eradication of H. pylori with double or triple regimens, without metronidazole, were randomly assigned to receive tripotassium dicitrato bismuthate 600 mg t.d.s. + metronidazole 500 mg t.d.s. + tetracycline hydrochloride 500 mg t.d. s. combined with either omeprazole 20 mg b.d. (group O, 78 patients) or ranitidine 300 mg b.d. (group R, 78 patients) for 14 days. H. pylori eradication was verified by histology, rapid urease test and 13C-urea breath test. STATISTICS: t-test, chi2-test. RESULTS: A total of 143 patients had a post-treatment endoscopy. Eradication rates were: intention-to-treat: group O 77% (67-87), group R 76% (66-85), P=0.85; per protocol analysis: group O 86% (77-95), group R 82 (71-93), P=0.58. Side-effects were frequent but mild. CONCLUSIONS: Omeprazole 20 mg b.d. and ranitidine 300 mg b.d. were equally effective as antisecretory agents combined in a second-line quadruple eradication regimen.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Helicobacter Infections/drug therapy , Omeprazole/therapeutic use , Ranitidine/therapeutic use , Administration, Oral , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Ulcer Agents/administration & dosage , Anti-Ulcer Agents/pharmacology , Drug Administration Schedule , Drug Therapy, Combination , Duodenal Ulcer/etiology , Duodenitis/etiology , Female , Gastric Acid/metabolism , Helicobacter pylori/drug effects , Humans , Male , Metronidazole/administration & dosage , Middle Aged , Omeprazole/administration & dosage , Omeprazole/pharmacology , Organometallic Compounds/administration & dosage , Ranitidine/administration & dosage , Ranitidine/pharmacology , Tetracycline/administration & dosage , Treatment Outcome
3.
Gastrointest Endosc ; 50(2): 165-72, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10425407

ABSTRACT

BACKGROUND: Barrett's esophagus is a premalignant condition. It has been reported that several methods of endoscopic ablation in combination with acid suppression result in replacement of specialized columnar epithelium by squamous epithelium. The aim of this study was to assess whether ablation of Barrett's mucosa by means of heat probe and acid suppression restores normal esophageal mucosa. METHODS: Thirteen patients with Barrett's epithelium but not dysplasia were enrolled in the study. Helicobacter pylori was eradicated when discovered. Thermal energy was applied using a heat probe (pulses of 5 to 10 joules). Four-quadrant biopsies were obtained at 1 to 2 cm intervals 1 to 3 months after the last treatment session. All patients continuously took omeprazole, 40 mg/day. RESULTS: Macroscopically, ablation of Barrett's mucosa was achieved in all patients after 1 to 5 sessions. Three of the 13 patients had residual specialized columnar epithelium beneath the restored mucosa but not overexpression of p53 and c-erbB-2. During follow-up (6 to 36 months) two patients in whom the length of Barrett's mucosa was greater than 2.5 cm relapsed after omeprazole discontinuation, whereas another two with length of less than 2.5 cm did not. One patient with residual Barrett's islands developed low-grade dysplasia. CONCLUSIONS: Heat probe is an effective and inexpensive method for Barrett's ablation. Islands of residual specialized columnar epithelium were found in 23% of patients. The length of Barrett's epithelium determines relapse after omeprazole discontinuation. (Gastrointest Endosc 1999;50:165-72).


Subject(s)
Barrett Esophagus/surgery , Electrocoagulation/instrumentation , Endoscopes , Esophagoscopes , Adult , Aged , Barrett Esophagus/pathology , Biopsy , Cell Transformation, Neoplastic/pathology , Epithelium/pathology , Esophagus/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Precancerous Conditions/pathology , Precancerous Conditions/surgery , Receptor, ErbB-2/analysis , Treatment Outcome , Tumor Suppressor Protein p53/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...